First Tracks Biotherapeutics Announces $200 Million Private PlacementGlobeNewsWire · Oct 15, 2026
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The ReceptorSeeking Alpha · Oct 14, 2026
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study GoalsDefense World · Oct 13, 2026
First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study GoalsMarketBeat · Oct 12, 2026
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On MondayBenzinga · Oct 12, 2026
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026Globe News Wire · Oct 11, 2026First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.